肿瘤异常蛋白联合荧光原位杂交技术对尿路上皮癌的诊断价值

doi:10.3760/cma.j.cn441417-20250107-13004

摘要/Abstract

摘要：

目的　探讨肿瘤异常蛋白（tumor abnormal protein，TAP）联合荧光原位杂交技术（fluorescent in situ hybridization，FISH）在尿路上皮癌（urothelial carcinoma，UC）中的诊断价值。方法　收集2021年9月至2023年7月在淄博市中心医院泌尿外科就诊的患者，收集TAP相关数据715例（其中男593例，年龄17～89岁，平均年龄69岁；女122例，年龄27～93岁，平均年龄58岁），FISH相关数据318例（其中男227例，年龄36～97岁，平均年龄67岁；女91例，年龄37～86岁，平均年龄69岁），其中有病理诊断的TAP数据257例和FISH数据122例。比较单项检测和联合检测的灵敏度和特异度。检测患者血液样本中TAP水平，筛选出231例有完整临床资料的数据进行分析，对患者进行综合病理评估，包括年龄、性别、影像学肿瘤大小、肿瘤恶性程度及是否有浸润，分析TAP表达水平与各种临床特征之间的相关性。采用独立样本t检验进行统计学分析。结果　246例UC患者TAP水平高于11例非癌患者［（213.3±76.95）μm²比（104.0±19.81）μm²］，差异有统计学意义（P<0.01）。TAP检测、FISH检测、联合检测的灵敏度分别为92.28%（227/246）、87.23%（82/94）、98.78%（81/82），联合检测的灵敏度高于两者单独检测，而FISH检测的特异度最高［92.86%（26/28）］。在231例患者中，TAP的高表达与高龄（年龄≥40岁）、肿瘤恶性程度有相关性（P=0.006、0.003）。结论　血清TAP可作为UC的生物标志物；TAP联合FISH检测对UC有较高的灵敏度，可以有效提高UC的诊断；TAP与性别、影像学肿瘤大小及肿瘤是否浸润均无显著相关性，与年龄、肿瘤恶性程度有相关性。

关键词: 尿路上皮癌, 肿瘤异常蛋白, 荧光原位杂交技术, 诊断

Abstract:

Objective　To investigate the clinical value of tumor abnormal protein (TAP) combined with fluorescent in situ hybridization (FISH) detection in the diagnosis of urothelial carcinoma (UC). Methods　Patients who visited the department of urology in Zibo Central Hospital from September 2021 to July 2023 were collected. Data related to TAP were collected from 715 cases (including 593 males, aged 17 to 89 years, with an average age of 69 years old; 122 females, aged 27 to 93 years, with an average age of 58 years old), and data related to FISH were collected from 318 cases (including 227 males, aged 36 to 97 years, with an average age of 67 years old; 91 females, aged 37 to 86 years, with an average age of 69 years old). Among them, 257 cases had pathological diagnoses for TAP and 122 cases had pathological diagnoses for FISH data. The sensitivities and specificities of individual detection and combined detection were compared. The TAP level in the blood samples of the patients was detected, and data from 231 cases with complete clinical information were screened out for analysis. A comprehensive pathological assessment was conducted for the patients, including age, gender, tumor size on imaging, malignant degree of tumor, and whether there was infiltration. The correlations between the TAP expression level and various clinical characteristics were analyzed. Statistical analysis was performed using the independent sample t-test. Results　The TAP level of 246 UC patients was higher than that of 11 non-cancer patients [(213.3±76.95) μm² vs. (104.0±19.81) μm²], with a statistically significant difference (P<0.01). The sensitivities of TAP detection, FISH detection, and combined detection were 92.28% (227/246), 87.23% (82/94), and 98.78% (81/82), respectively. The sensitivity of combined detection was higher than that of individual detection, while the specificity of FISH detection was the highest [92.86% (26/28)]. Among the 231 patients, the high expression of TAP was correlated with advanced age (age ≥40 years old) and the malignant degree of tumor (P=0.006 and 0.003). Conclusions　Serum TAP can be used as a biomarker for UC. TAP combined with FISH detection has a high sensitivity in UC, which can effectively improve the diagnosis. TAP is not significantly correlated with gender, imaging tumor size, or tumor invasion, but is correlated with age and malignant degree of tumor.

Key words: Urothelial carcinoma, , Tumor abnormal protein, , Fluorescent in situ hybridization, , Diagnosis

罗璇仪李静尹迎春曹彰.

肿瘤异常蛋白联合荧光原位杂交技术对尿路上皮癌的诊断价值 [J]. 国际医药卫生导报, 2025, 31(13): 2127-2131.

Luo Xuanyi, Li Jing, Yin Yingchun, Cao Zhang.

Clinical value of tumor abnormal protein combined with fluorescent in situ hybridization detection for diagnosing urothelial carcinoma [J]. International Medicine and Health Guidance News, 2025, 31(13): 2127-2131.

参考文献

[1] Ozgun G, Isharwal S, Eigl BJ. Editorial: therapies and influences in urothelial carcinoma[J]. Front Oncol, 2022, 12:1126494. DOI: 10.3389/fonc.2022.1126494.

[2] O'Donnell PH, Loriot Y, Csoszi T, et al. Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: post hoc analysis of KEYNOTE-052 and LEAP-011[J]. Cancer, 2025, 131(1):e35601. DOI: 10.1002/cncr.35601.

[3] Wu Y, Luo Y, Li T. A metabolic reprogramming-related gene signature correlates with prognosis and proliferation of BLCA[J]. Discov Oncol, 2024, 15(1):338. DOI: 10.1007/s12672-024-01219-2.

[4] Al-Maghrabi JA, Khabaz MN. Clinical significance of galectin-3 expression in urinary bladder carcinoma[J]. J Int Med Res, 2023, 51(2):3000605231153323. DOI: 10.1177/03000605231153323.

[5] Shang D, Liu Y, Xu X, et al. Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma[J]. Cancer Cell Int, 2021, 21(1):465. DOI: 10.1186/s12935-021-02169-3.

[6] Chen R, Jiang C, Zhu Q, et al. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer[J]. Medicine (Baltimore), 2020, 99(29):e21231. DOI: 10.1097/MD.0000000000021231.

[7] Cheng Y, Chen Y, Zang G, et al. Increased expression of TAP is predictive of poor prognosis in patients with non-small cell lung cancer[J]. Cancer Manag Res, 2020, 12:1941-1946. DOI: 10.2147/CMAR.S239593.

[8] Cheng Y, Chen B, Fang Q, et al. Analysis of tumor abnormal protein expression and epidermal growth factor receptor mutation status in non-small cell lung cancer[J]. Discov Oncol, 2024, 15(1):274. DOI: 10.1007/s12672-024-01094-x.

[9] Fu L, Zhang C, Wang Z, et al. Clinical application of serum tumor abnormal protein in prostate cancer patients[J]. BMC Cancer, 2024, 24(1):665. DOI: 10.1186/s12885-024-12418-z.

[10] Rolph MJ, Bolfa P, Cavanaugh SM, et al. Fluorescent in situ hybridization for the detection of intracellular bacteria in companion animals[J]. Vet Sci, 2024, 11(1):52. DOI: 10.3390/vetsci11010052.

[11] Yang T, Li Y, Li J, et al. Diagnostic value comparison of urothelium carcinoma among urine exfoliated cells fluorescent in situ hybridization (FISH) examination, computerized tomography (CT) scan, and urine cytologic examination[J]. Med Sci Monit, 2018, 24:5788-5792. DOI: 10.12659/MSM.910134.

[12]赵明,何向蕾,张大宏,等.WHO(2016)泌尿男性生殖系统肿瘤组织学分类解读[J].临床与实验病理学杂志,2017,33(2):119-124. DOI:10.13315/j.cnki.cjcep.2017.02.001.

[13]方三高,于永娟,王丛.WHO(2022)泌尿系统和男性生殖器官肿瘤分类[J].诊断病理学杂志,2023,30(4):410-416. DOI:10.3969/j.issn.1007-8096.2023.04.035.

[14] Cheng Y, Fang Q, Chen Y, et al. High expression of tumor abnormal protein preoperatively predicts poor prognosis of patients with esophageal squamous cell carcinoma[J]. Front Surg, 2021, 8:609719. DOI: 10.3389/fsurg.2021.609719.

[15] Benjamin DJ, Hsu R. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy[J]. Front Immunol, 2023, 14:1258388. DOI: 10.3389/fimmu.2023.1258388.

[16] Alhalabi O, Rafei H, Shah A, et al. Targeting advanced urothelial carcinoma-developing strategies[J]. Curr Opin Oncol, 2019, 31(3):207-215. DOI: 10.1097/CCO.0000000000000532.

[17] Zhang L, Guo X, Min Y, et al. Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer[J]. Int J Clin Exp Med, 2015, 8(10):18528-18532.

[18] Wu XY, Huang XE. Clinical application of serum tumor abnormal protein (TAP) in colorectal cancer patients[J]. Asian Pac J Cancer Prev, 2015, 16(8):3425-3428. DOI: 10.7314/apjcp.2015.16.8.3425.

[19] Chen WX, Yang LG, Cheng L, et al. Tumor abnormal protein in the diagnosis of breast cancer in patients with a palpable mass[J]. Ann Clin Lab Sci, 2019, 49(3):297-301.

[20] Ma A, Fan D, Yan F. A study of the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer[J]. Oncol Lett, 2018, 16(4):5186-5190. DOI: 10.3892/ol.2018.9250.

[21] Fu L, Zhang C, Wang Z, et al. Clinical application of serum tumor abnormal protein in prostate cancer patients [J]. BMC Cancer, 2024, 24(1): 665.DOI:10.1186/s12885-024-12418-z

[22] Zhang M, Wang X, Wang Z. Early study of tumor abnormal protein in gastric adenocarcinoma[J]. Onco Targets Ther, 2021, 14:1719-1726. DOI: 10.2147/OTT.S297413.

[23] Zhang Z, Tian C, Liu Y, et al. Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis[J]. Front Oncol, 2023, 13:1290791. DOI: 10.3389/fonc.2023.1290791.

[24]王日玮,夏云,石大友,等.肿瘤异常糖链糖蛋白联合中性粒细胞淋巴细胞比率对结直肠癌的诊断价值[J].中国当代医药,2024,31(29):63-66. DOI:10.3969/j.issn.1674-4721.2024.29.016.

[25]薛金秋,顾朱彤,徐凛峰.乳腺癌患者化疗前后肿瘤异常蛋白表达变化及临床意义研究[J].中国肿瘤外科杂志,2022,14(1):78-81. DOI:10.3969/j.issn.1674-4136.2022.01.016.

[26] Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update[J]. Eur Urol, 2023, 84(1):49-64. DOI: 10.1016/j.eururo.2023.03.013.

[27] Gu C, Xie L, Li B, et al. Quantification of tumor abnormal proteins in the diagnosis and postoperative prognostic evaluation of gastric cancer[J]. Clin Med Insights Oncol, 2022, 16:11795549221104440. DOI: 10.1177/11795549221104440.